Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

Table 2

Fugl-Meyer Assessment score at baseline and after treatment in the NeuroAid and the placebo group.

FMA	NeuroAid (no.=100)	Placebo (no.=50)	𝑃 value
Baseline	53.69±23.01	54.96±24.27	.755
4 weeks after intervention	77.13±19.22	63.50±24.21	<.001*
8 weeks after intervention	82.51±14.27	72.06±21.41	.001*
12 weeks after intervention	86.22±12.34	74.36±18.1	<.001*

FMA: Fugl-Meyer assessment. *Statistically significant.